Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: A representative, single institution case series

Vaccine

Volumn 27, Issue SUPPL. 1, 2009, Pages

  Sideri, Mario ^a   Cristoforoni, Paolo ^a   Casadio, Chiara ^a   Boveri, Sara ^a   Igidbashian, Sarah ^a   Schmitt, Marcus ^c   Gheit, Tarik ^a   Tommasino, Massimo ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cervical cancer; HPV genotype; HPV vaccine

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER STAGING; DNA EXTRACTION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIXED INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS; UTERINE CERVIX; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; DNA, VIRAL; FEMALE; GENOTYPE; GEOGRAPHY; HUMANS; ITALY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 66049119150     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.028     Document Type: Article

References (18)

1. Ferlay J., Bray P., Pizani P., and Parkin D.M. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5, Version 2.0 (2004), IARC Press, Lyon, France
2. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 August 20 (2) (2004) 278-285
3. Muñoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 February 6 (6) (2003) 518-527
4. Clifford G.M., Smith J.S., Plummer M., Muñoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 January 13 (1) (2003) 6373
5. Stanley M. HPV vaccines. Best Pract Res Clin Obstet Gynaecol 20 April (2) (2006) 279-293
6. Stanley M.A. Human papillomavirus vaccines. Rev Med Virol 16 May-June (3) (2006) 139-149
7. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 May (19) (2007) 1928-1943
8. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 May (19) (2007) 1915-1927
9. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 April (9518) (2006) 1247-1255
10. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 June (9580) (2007) 2161-2170 [Erratum in: Lancet 2007;370(October (9596)):1414]
11. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccine 3 July-August (4) (2007) 109-115
12. Del Mistro A., Salamanca H.F., Trevisan R., Bertorelle R., Parenti A., Bonoldi E., et al. Human papillomavirus typing of invasive cervical cancers in Italy. Infect Agent Cancer 1 December (2006) 9
13. Tornesello M.L., Duraturo M.L., Botti G., Greggi S., Piccoli R., De Palo G., et al. Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol 78 December (12) (2006) 1663-1672
14. Gheit T., Landi S., Gemignani F., Snijders P.J., Vaccarella S., Franceschi S., et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 44 June (6) (2006) 2025-2031
15. Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, et al. Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat, in press.
16. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 March (2005) 731-738
17. Coupé V.M., Berkhof J., Bulkmans N.W., Snijders P.J., and Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98 February 12 (3) (2008) 646-651
18. Jeronimo J., Massad S., and Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol 197 July (1) (2007) 47.e1-47.e8